gbr 12935 has been researched along with Idiopathic Parkinson Disease in 8 studies
1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine : An N-alkylpiperazine that consists of piperazine bearing 2-(benzhydryloxy)ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent and selective inhibitor of dopamine uptake (KD = 5.5 nM in rat striatal membranes).
| Excerpt | Relevance | Reference |
|---|---|---|
| "[3H]GBR 12935 binding was decreased in the putamen and caudate nucleus of subjects with Parkinson's disease (33 and 46% of control values, respectively) and progressive supranuclear palsy (38 and 57% of control values, respectively)." | 1.27 | [3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. ( Agid, Y; Javoy-Agid, F; Laduron, PM; Laterre, C; Maloteaux, JM; Vanisberg, MA, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allard, PO | 1 |
| Rinne, J | 1 |
| Marcusson, JO | 1 |
| Stasi, K | 1 |
| Mitsacos, A | 1 |
| Giompres, P | 1 |
| Kouvelas, ED | 1 |
| Triarhou, LC | 1 |
| Falkenburger, BH | 1 |
| Barstow, KL | 1 |
| Mintz, IM | 1 |
| Niznik, HB | 1 |
| Fogel, EF | 1 |
| Fassos, FF | 1 |
| Seeman, P | 2 |
| Pearce, RK | 1 |
| Jellinger, K | 1 |
| Tourtellotte, WW | 1 |
| Maloteaux, JM | 1 |
| Vanisberg, MA | 1 |
| Laterre, C | 1 |
| Javoy-Agid, F | 1 |
| Agid, Y | 1 |
| Laduron, PM | 1 |
| Hirai, M | 1 |
| Kitamura, N | 1 |
| Hashimoto, T | 1 |
| Nakai, T | 1 |
| Mita, T | 1 |
| Shirakawa, O | 1 |
| Yamadori, T | 1 |
| Amano, T | 1 |
| Noguchi-Kuno, SA | 1 |
| Tanaka, C | 1 |
| Janowsky, A | 1 |
| Vocci, F | 1 |
| Berger, P | 1 |
| Angel, I | 1 |
| Zelnik, N | 1 |
| Kleinman, JE | 1 |
| Skolnick, P | 1 |
| Paul, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Disclosure of Dopamine Transporter Imaging Studies in PD Clinical Trials[NCT00354003] | 800 participants (Anticipated) | Observational | 2006-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for gbr 12935 and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type.
Topics: Aged; Alzheimer Disease; Humans; Ligands; Parkinson Disease; Piperazines; Putamen; Receptors, Dopami | 1994 |
Partial restoration of striatal GABAA receptor balance by functional mesencephalic dopaminergic grafts in mice with hereditary parkinsonism.
Topics: Animals; Autoradiography; Brain Tissue Transplantation; Corpus Striatum; Fetal Tissue Transplantatio | 1999 |
Dendrodendritic inhibition through reversal of dopamine transport.
Topics: Animals; Biological Transport; Calcium; Carrier Proteins; Dendrites; Dopamine; Dopamine D2 Receptor | 2001 |
The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus.
Topics: Affinity Labels; Aged; Azides; Binding Sites; Binding, Competitive; Carrier Proteins; Caudate Nucleu | 1991 |
Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Binding Sites; Dopamine; Female; Humans; Levodopa; Ligands; Male; Mi | 1990 |
[3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy.
Topics: Animals; Binding Sites; Corpus Striatum; Dopamine; Humans; In Vitro Techniques; Male; Parkinson Dise | 1988 |
[3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics.
Topics: Aged; Animals; Binding Sites; Binding, Competitive; Corpus Striatum; Female; Humans; In Vitro Techni | 1988 |
[3H]GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease.
Topics: Caudate Nucleus; Cell Membrane; Corpus Striatum; Humans; Kinetics; Ligands; Nucleus Accumbens; Parki | 1987 |